Pharma Business review is using cookies

ContinueLearn More
Close

News

September 19, 2018

Zealand’s dasiglucagon succeeds in phase 3 trial for severe hypoglycemia

Zealand Pharma, a Copenhagen-based biotechnology company, said that a pivotal phase 3 trial evaluating dasiglucagon in patients with severe hypoglycemia in diabetes has achieved primary and key secondary endpoints.

Zealand’s dasiglucagon succeeds in phase 3 trial for severe hypoglycemia